Navigation Links
New study argues for CT colonography as primary colon cancer screening test
Date:4/23/2009

CT colonography allows radiologists to predict, with a high degree of confidence, whether or not a polyp needs to be evaluated through colonoscopy or removed through polypectomy, according to a study performed at the University of Wisconsin School of Medicine and Public Health in Madison, WI.

The study included 479 patients with 739 CT colonography (CTC) detected lesions. "In our study, we found that when a clinically important polyp is found with CT colonography, a corresponding polyp will be identified at colonoscopy greater than 90% of the time," said Steven M. Wise, MD, lead author of the study. Results from the study showed that 677/739 lesions (91.6%) detected on CTC were also found during optical colonoscopy or surgery. "This means that when a radiologist calls a CTC exam positive, the endoscopist can be confident that a treatable polyp is present. The CTC exam can also show the endoscopist where the polyp is located," said Dr. Wise.

"The results of this study add even more strength to the argument that CTC is an effective primary screening test for colon cancer that can be used to select out patients who will need colonoscopy and polypectomy. CTC is a good screening option for those patients who wish to avoid the sedation and higher complication rate associated with colonoscopy," he said.

"The finding that the vast majority of polyps found on CTC do represent true polyps will help better establish CTC as a first line screening test for colon cancer in clinical practice. Hopefully, this will increase the number of people screened for colon cancer and therefore enable early detection and prevention of this deadly disease," said Dr. Wise.


'/>"/>

Contact: Heather Curry
hcurry@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study
2. Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
3. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
4. BUSM study finds photographs of UV exposure can impact sunburns in preteens
5. Telesso initiates post-market head-to-head peripheral IV catheter study
6. FDA Grants Ethicon Endo-Surgery Approval of Its IDE Application to Commence Study of Notes Toolbox(TM)
7. New Study Shows Fish Oil Improves Cholesterol Levels in Professional Football Players
8. Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
9. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
10. Mexicos health insurance success offers lessons for US reforms, Lancet study suggests
11. Study: Lizards bask for more than warmth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... share of all holidays (IBT World Travel Trends Report). As travelers visit both ... a range in temperatures, and prolonged sun exposure. In response, the outdoor industry ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: